Orchid Pharma vs Beta Drugs vs Gujarat Kidney: Which Stock Should You Track

Orchid Pharma vs Beta Drugs vs Gujarat Kidney and Super Speciality starts with the core numbers most investors compare within the pharma and healthcare segment: market capitalisation, valuation multiples, profitability, dividend yield and the latest quarterly results. Figures below are sourced as of October 2026 and will shift with daily price moves.

All three names sit in the pharma and healthcare bucket, which makes them a natural set to place side by side rather than a random trio of unrelated businesses. The sections below cover the company profiles, a valuation table, the latest quarter and a five-quarter trend for revenue and net profit.

Click Here – Get Free Investment Predictions

Orchid Pharma, Beta Drugs and Gujarat Kidney and Super Speciality: Company Overview

Orchid Pharma is a listed Indian company in the pharma and healthcare space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 5,877 crore, a return on equity of 1.34% and a book value of Rs 261.22 per share. Its quarterly revenue moved from Rs 274.76 crore in June 2025 to Rs 306.00 crore in June 2026, a change of +11.4%.

Beta Drugs is a listed Indian company in the pharma and healthcare space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 2,104 crore, a return on equity of 16.95% and a book value of Rs 221.65 per share. Its quarterly revenue moved from Rs 103.20 crore in June 2025 to Rs 127.13 crore in June 2026, a change of +23.2%.

Gujarat Kidney and Super Speciality is a listed Indian company in the pharma and healthcare space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 1,429 crore, a return on equity of 6.14% and a book value of Rs 32.03 per share. Its quarterly revenue moved from Rs 15.27 crore in June 2025 to Rs 34.98 crore in June 2026, a change of +129.1%.

Orchid Pharma vs Beta Drugs vs Gujarat Kidney and Super Speciality: Valuation and Profitability Snapshot

Metric	Orchid Pharma	Beta Drugs	Gujarat Kidney and Super Speciality
Market Cap (approx.)	Rs 5,877 crore	Rs 2,104 crore	Rs 1,429 crore
PE Ratio (TTM)	548.30	45.47	85.50
PB Ratio	3.76	8.56	5.66
Return on Equity (ROE)	1.34%	16.95%	6.14%
EPS (TTM, Rs)	1.79	41.74	2.12
Dividend Yield	0.00%	0.00%	0.00%
Debt to Equity	0.28	0.60	0.12
Book Value per Share (Rs)	261.22	221.65	32.03

Check the Univest Screener for Live Data

On valuation, Orchid Pharma trades at a PE of 548.30 and a PB of 3.76, Beta Drugs at a PE of 45.47 and a PB of 8.56, while Gujarat Kidney and Super Speciality trades at a PE of 85.50 and a PB of 5.66. On return on equity, the three post 1.34%, 16.95% and 6.14% respectively, and on dividend yield they stand at 0.00%, 0.00% and 0.00%. Orchid Pharma has the highest market capitalisation of the three at Rs 5,877 crore, while Gujarat Kidney and Super Speciality has the lowest at Rs 1,429 crore. Orchid Pharma has the highest PE ratio of the three at 548.30, while Beta Drugs has the lowest at 45.47. Beta Drugs has the highest return on equity of the three at 16.95%, while Orchid Pharma has the lowest at 1.34%. Beta Drugs has the highest debt to equity ratio of the three at 0.60, while Gujarat Kidney and Super Speciality has the lowest at 0.12. Debt to equity is 0.28, 0.60 and 0.12 for the three respectively.

Orchid Pharma vs Beta Drugs vs Gujarat Kidney and Super Speciality: Latest Quarterly Results

Company	Latest Quarter Revenue	Latest Quarter Net Profit	YoY Change (Revenue)	QoQ Change (Revenue)	YoY Change (Net Profit)
Orchid Pharma	Rs 306.00 crore	Rs 2.58 crore	+11.4%	-18.6%	NA
Beta Drugs	Rs 127.13 crore	Rs 16.49 crore	+23.2%	+31.3%	+40.9%
Gujarat Kidney and Super Speciality	Rs 34.98 crore	Rs 5.32 crore	+129.1%	+11.8%	-1.5%

Quarterly figures above are the most recent reported quarter for each company (Q1 FY27, quarter ended June 2026), compared with the year-ago and preceding quarter. A percentage change in net profit is shown as NA where the comparison quarter was a loss or the latest quarter is a loss, since the percentage is not meaningful in that case.

Orchid Pharma vs Beta Drugs vs Gujarat Kidney and Super Speciality: Five-Quarter Revenue and Net Profit Trend

The five-quarter view below shows how revenue and net profit moved from June 2025 to June 2026 for each company in Orchid Pharma vs Beta Drugs vs Gujarat Kidney and Super Speciality, which helps separate a one-quarter move from a steadier pattern.

Quarterly revenue (Rs crore)

Quarter	Orchid Pharma	Beta Drugs	Gujarat Kidney and Super Speciality
June 2025	Rs 274.76 crore	Rs 103.20 crore	Rs 15.27 crore
September 2025	Rs 204.29 crore	Rs 106.38 crore	Rs 13.02 crore
December 2025	Rs 212.88 crore	Rs 89.58 crore	Rs 23.31 crore
March 2026	Rs 376.10 crore	Rs 96.85 crore	Rs 31.29 crore
June 2026	Rs 306.00 crore	Rs 127.13 crore	Rs 34.98 crore

Quarterly net profit (Rs crore)

Quarter	Orchid Pharma	Beta Drugs	Gujarat Kidney and Super Speciality
June 2025	-Rs 6.89 crore	Rs 11.70 crore	Rs 5.40 crore
September 2025	-Rs 3.33 crore	Rs 12.22 crore	Rs 2.88 crore
December 2025	-Rs 12.15 crore	Rs 8.52 crore	Rs 3.71 crore
March 2026	Rs 24.84 crore	Rs 9.05 crore	Rs 4.83 crore
June 2026	Rs 2.58 crore	Rs 16.49 crore	Rs 5.32 crore

Orchid Pharma reported revenue of Rs 274.76 crore in June 2025 and Rs 306.00 crore in June 2026, a change of +11.4% across the period. Its highest quarterly revenue in this window was Rs 376.10 crore in March 2026. Net profit stood at Rs 2.58 crore in June 2026, which is a net profit margin of 0.84%. Orchid Pharma reported a net loss in June 2025, September 2025 and December 2025.

Beta Drugs reported revenue of Rs 103.20 crore in June 2025 and Rs 127.13 crore in June 2026, a change of +23.2% across the period. Its highest quarterly revenue in this window was Rs 127.13 crore in June 2026. Net profit stood at Rs 16.49 crore in June 2026, which is a net profit margin of 12.97%.

Gujarat Kidney and Super Speciality reported revenue of Rs 15.27 crore in June 2025 and Rs 34.98 crore in June 2026, a change of +129.1% across the period. Its highest quarterly revenue in this window was Rs 34.98 crore in June 2026. Net profit stood at Rs 5.32 crore in June 2026, which is a net profit margin of 15.21%.

Download the Univest iOS App or Univest Android App to track Orchid Pharma, Beta Drugs and Gujarat Kidney and Super Speciality live prices.

What Should Investors Look at Beyond These Numbers?

Beyond the metrics above, investors comparing these three pharma and healthcare names should track quarter-on-quarter revenue and margin trends, management commentary on demand and cost drivers, and factors specific to the segment such as regulatory approvals, export orders, patient volumes and capacity utilisation. A single-quarter snapshot can shift quickly, and smaller companies in particular can show wide swings from one quarter to the next.

It also helps to read the latest quarterly filings and investor presentations of Orchid Pharma, Beta Drugs and Gujarat Kidney and Super Speciality directly, since the figures here come from standardised data and do not capture company-specific context such as one-time items, order timing or promoter actions.

Conclusion

Orchid Pharma vs Beta Drugs vs Gujarat Kidney and Super Speciality highlights how differently three companies in the same pharma and healthcare segment can look across valuation, profitability and dividend metrics, even when operating in a similar space. This comparison does not declare a winner; investors should weigh these figures against their own research and risk appetite. Please read the disclaimer below before making any investment decision.

FAQs on Orchid Pharma vs Beta Drugs vs Gujarat Kidney and Super Speciality

What is the market cap difference between Orchid Pharma, Beta Drugs and Gujarat Kidney and Super Speciality?

Ans. As of October 2026, Orchid Pharma has a market cap of approximately Rs 5,877 crore, Beta Drugs is at approximately Rs 2,104 crore, and Gujarat Kidney and Super Speciality is at approximately Rs 1,429 crore.

What are the PE and PB ratios of Orchid Pharma, Beta Drugs and Gujarat Kidney and Super Speciality?

Ans. As of October 2026, the PE ratios stand at 548.30, 45.47 and 85.50 respectively, and the price to book ratios stand at 3.76, 8.56 and 5.66 respectively.

Which of the three has the highest ROE?

Ans. Orchid Pharma, Beta Drugs and Gujarat Kidney and Super Speciality post ROE of 1.34%, 16.95% and 6.14% respectively as of October 2026. Beta Drugs has the highest return on equity of the three at 16.95%, while Orchid Pharma has the lowest at 1.34%.

Which of these three stocks pays the highest dividend yield?

Ans. Orchid Pharma, Beta Drugs and Gujarat Kidney and Super Speciality carry dividend yields of 0.00%, 0.00% and 0.00% respectively.

What is the debt to equity ratio for Orchid Pharma, Beta Drugs and Gujarat Kidney and Super Speciality?

Ans. Orchid Pharma carries a debt to equity of 0.28, Beta Drugs of 0.60, and Gujarat Kidney and Super Speciality of 0.12.

What were the latest quarterly revenue and net profit of Orchid Pharma, Beta Drugs and Gujarat Kidney and Super Speciality?

Ans. For Q1 FY27 (quarter ended June 2026), Orchid Pharma reported revenue of Rs 306.00 crore and net profit of Rs 2.58 crore, Beta Drugs reported revenue of Rs 127.13 crore and net profit of Rs 16.49 crore, and Gujarat Kidney and Super Speciality reported revenue of Rs 34.98 crore and net profit of Rs 5.32 crore.

Does this comparison recommend one of Orchid Pharma, Beta Drugs and Gujarat Kidney and Super Speciality?

Ans. This comparison does not declare one stock ahead of another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor's own criteria and research.